211-225 of 937
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC Action CenterEarly aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Michael Koren, MD
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
ACC Action CenterNo effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Javed Butler, MD
Beyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program
CME/CEBeyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program
Dmitry M. Yaranov, MD
Allergic Reactions and Cardiac Concerns: Exploring the Heart Disease Link
Heart MattersAllergic Reactions and Cardiac Concerns: Exploring the Heart Disease Link
Javed Butler, MD
Jeffrey Wilson, MD
Active Aging: Preventing Heart Failure in Older Women with Exercise
Heart MattersActive Aging: Preventing Heart Failure in Older Women with Exercise
Javed Butler, MD
Michael J. LaMonte, PhD, MPH
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Clinician's RoundtableImproving CKD Patient Outcomes with SGLT2 Inhibitors
Gates B. Colbert, MD
- advertisement
Cardiovascular Disease in T2D: Researchers Identify Potential Therapeutic Target for Underlying Cause
Heart MattersCardiovascular Disease in T2D: Researchers Identify Potential Therapeutic Target for Underlying Cause
New Guidance on Neurodevelopment Outcomes in Patients with Heart Defects
Heart MattersNew Guidance on Neurodevelopment Outcomes in Patients with Heart Defects
AHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD
Heart MattersAHA Identifies CKM Syndrome: A First Step in Managing Patients with CVD
Javed Butler, MD
Chiadi Ndumele, M.D., Ph.D., M.H.S.
CKM Syndrome Linked to Heart, Kidney, and Metabolic Diseases
Heart MattersCKM Syndrome Linked to Heart, Kidney, and Metabolic Diseases
Pharmacist-Prescribing and Hypertension Management: An Economic Benefit
Heart MattersPharmacist-Prescribing and Hypertension Management: An Economic Benefit
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Dave L. Dixon, PharmD, FACC, FCCP, FNLA, BCPS, BCACP, CDE, CLS
SELECT Trial: Semaglutide Lowers CVD Risk in Patients with Obesity
Heart MattersSELECT Trial: Semaglutide Lowers CVD Risk in Patients with Obesity
- advertisement
Peter Buch, MD, FACG, AGAF, FACP
Paul Kwo, MD
Improving Symptoms, Function, and Weight Loss in HFpEF Patients with Obesity
Heart MattersImproving Symptoms, Function, and Weight Loss in HFpEF Patients with Obesity
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Javed Butler, MD
A Discussion on Statins to Lower CVD Risk for HIV Patients
Heart MattersA Discussion on Statins to Lower CVD Risk for HIV Patients
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Steve Grinspoon, MD
